longwood: search

Harvard Medical School and Cellectricon collaborates Around Whole-Genome RNAi Screening Technology

Cellectricon has announced its collaboration with Harvard Medical School, the ICCB-Longwood Screening Facility. Harvard Medical School (ICCB-L) will utilize the Cellaxess®HT system, a system for high throughput transfection enabling reagent-free delivery of genetic material to a wide range of biologically relevant cell types.

Harvard Medical School and Cellectricon Collaborates Around Whole-Genome RNAi Screening Technology - CellaxessHT

GOTHENBURG, Sweden, Nov. 25 /CNW/ - Cellectricon, a leading provider of automated screening solutions for drug discovery, today announced its collaboration with Harvard Medical School, the ICCB-Longwood Screening Facility ("ICCB-L"). Harvard Medical School (ICCB-L) will utilize the Cellaxess(R)HT system, the world's first system for high throughput transfection enabling reagent-free delivery of genetic material to a wide range of biologically relevant cell types. "We are excited about the collaboration with Cellectricon and the opportunity we have to evaluate Cellaxess(R)HT for genome-wide RNAi delivery to biologically relevant cell types," says Caroline Shamu, Director of ICCB-L. "Cellectricon is extremely proud to collaborate with a world-class research institution such as Harvard Medical School (ICCB-L)," says Jonas Ohlsson, CEO at Cel

Search took 0.00 seconds.